Table 1:
Demographics and clinical data of LAPC patients.
| Variable | LAPC patients (n=415) | LAPC-1 (n=67) | LAPC-2 (n=60) | LAPC-3 (n=288) | p-value |
|---|---|---|---|---|---|
| Male, n (%) | 195 (47) | 33 (49) | 26 (43) | 135 (47) | 0.623 |
|
| |||||
| Race, n (%) | 0.367 | ||||
| Caucasian | 348 (84) | 62 (93) | 52 (87) | 236 (82) | |
|
| |||||
| Age (years) | 0.511 | ||||
| Mean (SD) | 65.2 (10.1) | 63.2 (9.7) | 65.6 (9.9) | 65.4 (10.7) | |
|
| |||||
| ECOG performance status, n (%) | 0.152 | ||||
| ECOG 0 | 131 (32) | 26 (39) | 23 (38) | 82 (29) | |
| ECOG 1 | 260 (63) | 39 (58) | 36 (60) | 185 (64) | |
| ECOG 2 | 21 (5) | 1 (1) | 1 (2) | 19 (7) | |
| ECOG 3 | 3 (1) | 1 (1) | 0 (0) | 2 (0) | |
|
| |||||
| CT-scan characteristics, n (%) | |||||
| Tumour size (mm), mean (SD) | 38 (14) | 34 (13) | 37 (12) | 40 (15) | 0.004 |
| Regional lymphadenopathy, n (%) | 111 (27) | 14 (21) | 13 (21) | 84 (29) | 0.177 |
| GI tract involvement, n (%) | 91 (22) | 8 (12) | 14 (23) | 69 (24) | 0.039 |
| Duodenum | 68 (75) | 3 (4) | 9 (15) | 56 (19) | |
| Stomach | 22 (24) | 4 (6) | 5 (8) | 13 (5) | |
| Small bowel | 1 (1) | 1 (1) | 0 (0) | 0 (0) | |
| Tumour site, n (%) | 0.288 | ||||
| Head | 174 (42) | 26 (39) | 27 (45) | 121 (42) | |
| Uncinate | 62 (15) | 10 (15) | 6 (10) | 46 (16) | |
| Neck | 51 (12) | 5 (8) | 12 (20) | 34 (12) | |
| Body | 115 (28) | 22 (33) | 15 (25) | 78 (27) | |
| Tail | 13 (3) | 3 (4) | 1 (2) | 9 (3) | |
| Atrophy of the pancreas, present, n (%) | 258 (62) | 36 (54) | 36 (60) | 186 (65) | 0.090 |
|
| |||||
| Involvement of major vessels, n (%) | |||||
| Abutment (≤180°) | 0.008 | ||||
| PV/SMV | 70 (17) | 19 (28) | 18 (30) | 33 (11) | |
| Celiac artery | 35 (8) | 9 (13) | 12 (20) | 14 (5) | |
| Superior mesenteric artery | 68 (16) | 17 (25) | 19 (32) | 32 (11) | |
| Common hepatic artery | 21 (5) | 5 (7) | 5 (8) | 11 (4) | |
| Encasement (>180°) | <0.001 | ||||
| PV/SMV | 282 (68) | 26 (39) | 54 (90) | 202 (70) | |
| Celiac artery | 164 (40) | 11 (16) | 31 (52) | 122 (42) | |
| Superior mesenteric artery | 196 (47) | 3 (4) | 15 (25) | 178 (62) | |
| Common hepatic artery | 213 (51) | 20 (30) | 39 (65) | 154 (53) | |
|
| |||||
| CA19–9 at diagnosis a | 0.430 | ||||
| Median (IQR), U/ml | 314 (66–1196) | 195 (47–530) | 325 (71–1220) | 462 (102–1455) | |
|
| |||||
| Induction chemotherapy, n (%) | 0.304 | ||||
| FFX-based | 189 (50) | 34 (51) | 25 (42) | 130 (45) | |
| FFX-Gem combination | 72 (19) | 11 (16) | 15 (25) | 46 (16) | |
| Gem-based | 117 (31) | 20 (30) | 12 (20) | 85 (30) | |
| Time administered, months | 0.694 | ||||
| Median (IQR) | 4 (3–6) | 5 (4–6) | 5 (4–6) | 4 (3–6) | |
|
| |||||
| Induction radiotherapy, n (%) | 222 (54) | 51 (76) | 41 (68) | 130 (45) | 0.001 |
| Modality, n (%) | 0.036 | ||||
| SBRT | 160 (72) | 40 (60) | 34 (57) | 86 (30) | |
| IMRT/standard RT | 62 (28) | 11 (16) | 7 (12) | 44 (15) | |
|
| |||||
| Time from NAT to OR, weeks | 0.745 | ||||
| Median (IQR) | 6 (5–8) | 6 (5–7) | 6 (5–8) | 6 (5–8) | |
|
| |||||
| Surgical exploration, n (%) | <0.0001 | ||||
| Yes | 116 (28) | 42 (63) | 24 (40) | 50 (17) | |
| No | 299 (72) | 25 (37) | 36 (60) | 238 (83) | |
|
| |||||
| OR outcome, n (%) | <0.0001 | ||||
| Resected | 84 (20) | 33 (49) | 19 (32) | 32 (11) | |
| Not-resected | 331 (80) | 34 (51) | 41 (68) | 256 (89) | |
LAPC: locally advanced pancreatic cancer; SD: standard deviation; ECOG: Eastern Cooperative Oncology Group; CT: computed tomography; GI: gastrointestinal; PV: portal vein; SMV: superior mesenteric vein; IQR: interquartile range; CA19-9: Carbohydrate antigen 19-9; SBRT: stereotactic body radiation therapy; IMRT: Intensity-modulated radiation therapy; RT: radiotherapy; NAT: neoadjuvant therapy; OR: operating room; a: 67 missing values at the time of baseline MDT. Values in bold are statistically significant.